{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:47:00Z","timestamp":1792424820111,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007123","name":"Stanley Medical Research Institute","doi-asserted-by":"publisher","award":["10T-002"],"award-info":[{"award-number":["10T-002"]}],"id":[{"id":"10.13039\/100007123","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.schres.2018.03.012","type":"journal-article","created":{"date-parts":[[2018,3,24]],"date-time":"2018-03-24T23:53:42Z","timestamp":1521935622000},"page":"395-402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":92,"special_numbering":"C","title":["Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders"],"prefix":"10.1016","volume":"199","author":[{"given":"Alan","family":"Breier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Liffick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom A.","family":"Hummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenifer L.","family":"Vohs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole F.","family":"Mehdiyoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Visco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmalee","family":"Metzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2018.03.012_bb0005","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.biopsych.2011.05.017","article-title":"Progressive brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia","volume":"70","author":"Andreasen","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2018.03.012_bb0010","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1001\/archgenpsychiatry.2011.150","article-title":"Progressive brain changes in children and adolescents with first-episode psychosis","volume":"69","author":"Arango","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2018.03.012_bb0015","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00726-001-0122-6","article-title":"Cystine\/glutamate exchange serves as the source for extracellular glutamate: modifications by repeated cocaine administration","volume":"23","author":"Baker","year":"2002","journal-title":"Amino Acids"},{"key":"10.1016\/j.schres.2018.03.012_bb0020","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.biopsych.2008.03.004","article-title":"N-acetyl cysteine as a glutathione precursor for schizophrenia\u2014a double-blind, randomized, placebo-controlled trial","volume":"64","author":"Berk","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2018.03.012_bb0025","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1189\/jlb.0212100","article-title":"The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes","volume":"92","author":"Beumer","year":"2012","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.schres.2018.03.012_bb0030","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1176\/appi.ajp.2012.11091337","article-title":"Combined cognitive remediation and functional skills training for schizophrenia: effects on cognition, functional competence, and real-world behavior","volume":"169","author":"Bowie","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2018.03.012_bb0035","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archpsyc.1991.01810270051007","article-title":"National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome","volume":"48","author":"Breier","year":"1991","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2018.03.012_bb0040","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2018.03.012_bb0045","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.biopsych.2014.05.023","article-title":"Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk","volume":"77","author":"Cannon","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2018.03.012_bb0050","doi-asserted-by":"crossref","DOI":"10.1155\/2008\/716458","article-title":"Inhibitory effect on cerebral inflammatory response following traumatic brain injury in rats: a potential neuroprotective mechanism of N-acetylcysteine","volume":"2008","author":"Chen","year":"2008","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.schres.2018.03.012_bb0055","series-title":"Proceedings of the International Congress on Schizophrenia Research","article-title":"Effects of N-acetyl cysteine as add-on to standard treatment on neurocognition in early psychosis","author":"Cleusix","year":"2017"},{"key":"10.1016\/j.schres.2018.03.012_bb0060","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/jcph.1008","article-title":"Repeated-dose oral N-acetylcysteine in Parkinson's disease: pharmacokinetics and effect on brain glutathione and oxidative stress","volume":"58","author":"Coles","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2018.03.012_bb0065","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/schbul\/sbx093","article-title":"N-acetylcysteine in a double-blind randomized placebo-controlled trial: toward biomarker-guided treatment in early psychosis","volume":"44","author":"Conus","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2018.03.012_bb0070","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1503\/jpn.100057","article-title":"N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action","volume":"36","author":"Dean","year":"2011","journal-title":"J. Psychiatry Neurosci."},{"issue":"3","key":"10.1016\/j.schres.2018.03.012_bb0075","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.psychres.2015.10.037","article-title":"Benefits of adjunctive N-acetylcysteine in a sub-group of clozapine-treated individuals diagnosed with schizophrenia","volume":"230","author":"Dean","year":"2015","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2018.03.012_bb0080","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1515\/BC.2003.059","article-title":"Glutathione pathways in the brain","volume":"384","author":"Dringen","year":"2003","journal-title":"Biol. Chem."},{"key":"10.1016\/j.schres.2018.03.012_bb0085","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00213-013-3261-z","article-title":"A double-blind, placebo controlled, randomized trial of Riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia","volume":"231","author":"Farokhnia","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2018.03.012_bb0090","series-title":"Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version","author":"First","year":"2002"},{"key":"10.1016\/j.schres.2018.03.012_bb0095","first-page":"42","article-title":"The relationship of structural brain imaging parameters to antipsychotic treatment response: a review","volume":"17","author":"Friedman","year":"1992","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.schres.2018.03.012_bb0100","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/schbul\/sbt001","article-title":"Pro-\/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia","volume":"40","author":"Garcia-Bueno","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2018.03.012_bb0105","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/archpsyc.61.1.17","article-title":"Comparison of progressive cortical gray matter loss in childhood-onset schizophrenia with that in childhood-onset atypical psychoses","volume":"61","author":"Gogtay","year":"2004","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2018.03.012_bb0110","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia?","volume":"153","author":"Green","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2018.03.012_bb0115","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.schres.2004.09.009","article-title":"Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS","volume":"72","author":"Green","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2018.03.012_bb0120","series-title":"National Institute of Mental Health","first-page":"217","article-title":"ECDEU assessment manual for psychopharacology, revised","author":"Guy","year":"1976"},{"key":"10.1016\/j.schres.2018.03.012_bb0125","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.schres.2016.03.023","article-title":"Progressive brain tissue loss in schizophrenia","volume":"173","author":"van Haren","year":"2016","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.schres.2018.03.012_bb1000","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00023210-200620050-00004","article-title":"Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia","volume":"20","author":"Horacek","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2018.03.012_bb0130","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/schbul\/sbm168","article-title":"What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia","volume":"34","author":"Hulshoff Pol","year":"2008","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2018.03.012_bb0135","article-title":"Characterization of white matter abnormalities in early-stage schizophrenia","author":"Hummer","year":"2016","journal-title":"Early Interv. Psychiatry"},{"key":"10.1016\/j.schres.2018.03.012_bb0140","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2018.03.012_bb0145","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.schres.2003.09.011","article-title":"The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery","volume":"68","author":"Keefe","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2018.03.012_bb0150","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/13803390500360539","article-title":"The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome","volume":"28","author":"Keefe","year":"2006","journal-title":"J. Clin. Exp. Neuropsychol."},{"key":"10.1016\/j.schres.2018.03.012_bb1005","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0920-9964(93)90058-Q","article-title":"Frontal lobemetabolism and cerebral morphology in schizophrenia: 31P MRS and MRI studies","volume":"10","author":"Keshavan","year":"1993","journal-title":"Schizophr Res."},{"key":"10.1016\/j.schres.2018.03.012_bb0155","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/sj.npp.1301624","article-title":"Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients","volume":"33","author":"Lavoie","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2018.03.012_bb0160","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1001\/archpsyc.62.4.361","article-title":"Antipsychotic drug effects on brain morphology in first-episode psychosis","volume":"62","author":"Lieberman","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2018.03.012_bb0165","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.schres.2015.01.005","article-title":"Effects of endurance training on brain structures in chronic schizophrenia patients and healthy controls","volume":"173","author":"Malchow","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2018.03.012_bb0170","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2018.03.012_bb0175","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.molimm.2015.01.028","article-title":"Complement in therapy and disease: regulating the complement system with antibody-based therapeutics","volume":"67","author":"Melis","year":"2015","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.schres.2018.03.012_bb0180","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1034\/j.1600-0447.2000.101004323.x","article-title":"Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning","volume":"101","author":"Morosini","year":"2000","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2018.03.012_bb0185","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3389\/fnins.2015.00372","article-title":"The role of inflammation in schizophrenia","volume":"9","author":"Muller","year":"2015","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.schres.2018.03.012_bb0190","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3747\/pdi.2009.00073","article-title":"Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study","volume":"30","author":"Nascimento","year":"2010","journal-title":"Perit. Dial. Int."},{"key":"10.1016\/j.schres.2018.03.012_bb0195","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2004.09.007","article-title":"Identification of separable cognitive factors in schizophrenia","volume":"72","author":"Nuechterlein","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2018.03.012_bb0200","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1126\/science.1835799","article-title":"NMDA antagonist neurotoxicity: mechanism and prevention","volume":"254","author":"Olney","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.schres.2018.03.012_bb0205","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/BF01061422","article-title":"Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine","volume":"34","author":"Olsson","year":"1988","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2018.03.012_bb0210","doi-asserted-by":"crossref","first-page":"440","DOI":"10.47102\/annals-acadmedsg.V38N5p440","article-title":"Imaging in schizophrenia: looking back and peering ahead","volume":"38","author":"Pantelis","year":"2009","journal-title":"Ann. Acad. Med. Singap."},{"key":"10.1016\/j.schres.2018.03.012_bb0215","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/schbul\/sbi034","article-title":"Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia","volume":"31","author":"Pantelis","year":"2005","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2018.03.012_bb0220","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jpsychires.2010.05.003","article-title":"Diffusion tensor imaging in the early phase of schizophrenia: what have we learned?","volume":"44","author":"Peters","year":"2010","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2018.03.012_bb0225","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pnpbp.2014.10.002","article-title":"Towards stage specific treatments: effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia","volume":"57","author":"Rapado-Castro","year":"2015","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2018.03.012_bb0230","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1017\/S0033291716002932","article-title":"Cognitive effects of adjunctive N-acetyl cysteine in psychosis","volume":"47","author":"Rapado-Castro","year":"2017","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2018.03.012_bb0235","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.schres.2017.07.008","article-title":"Treatment in early psychosis with N-acetyl-cysteine for 6months improves low-level auditory processing: pilot study","volume":"191","author":"Retsa","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2018.03.012_bb0240","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1192\/S0007125000292428","article-title":"Can computerised tomography be used to predict early treatment response in schizophrenia?","author":"Schroder","year":"1993","journal-title":"Br. J. Psychiatry Suppl."},{"key":"10.1016\/j.schres.2018.03.012_bb0245","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature16549","article-title":"Schizophrenia risk from complex variation of complement component 4","volume":"530","author":"Sekar","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.schres.2018.03.012_bb0250","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/oxfordjournals.schbul.a033382","article-title":"Outcome of schizophrenia in relation to brain abnormalities","volume":"25","author":"Staal","year":"1999","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2018.03.012_bb0255","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev.pharmtox.42.082701.160735","article-title":"Glutamatergic mechanisms in schizophrenia","volume":"42","author":"Tsai","year":"2002","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.schres.2018.03.012_bb0260","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.neuroimage.2006.03.041","article-title":"Progressive grey matter atrophy over the first 2\u20133years of illness in first-episode schizophrenia: a tensor-based morphometry study","volume":"32","author":"Whitford","year":"2006","journal-title":"NeuroImage"},{"key":"10.1016\/j.schres.2018.03.012_bb0265","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4088\/JCP.v64n0607","article-title":"Chlorpromazine equivalent doses for the newer atypical antipsychotics","volume":"64","author":"Woods","year":"2003","journal-title":"J. Clin. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996418301646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996418301646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T19:38:58Z","timestamp":1693597138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996418301646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":55,"alternative-id":["S0920996418301646"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2018.03.012","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2018.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}